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Introduction: 188Re is a promising radionuclide for metabolic therapy because of the emission of 
high energy beta-particles. The development of water-soluble polymers such as PEI-MP 
(polyethyleneimine, functionalised with methylphosphonate groups) that might be labeled with 
188Re are recent approaches, with a strong potential for metabolic radiotherapy.  
Aim:The aim of this study was to evaluate the efficacy of 188Re-PEI-MP, as therapeutic agent for 
osteosarcoma and bladder carcinoma using an in vivo model.  
Material and Methods: To proceed with the in vivo studies, it was investigated the cytotoxicity of 
PEI-MP in osteosarcoma cell line (MNNG-HOS) and bladder carcinoma cell line (CRL-1472) 
using the MTT test for different concentrations of PEI-MP (1 µM to 1000 µM) and incubation 
times (24h, 48h, 72h and 96h). Radiochemical purity of 188Re-PEI-MP was achieved using 
microchromatography (ITLC-SG/acetone and W3MM/citrate 1M). The in vivo studies 
were performed using six groups of Balb/c nu/nu mice: two normal groups were injected with 
Na188ReO4 (n=18) and 188Re-PEI-MP (n=17) respectively; two with osteosarcoma xenotransplants 
were injected with Na188ReO4 (n=17) and 188Re-PEI-MP (n=19) respectively; and two with bladder 
 
  
  
  
 
 
 
 
 
carcinoma xenotransplants were injected with Na188ReO4 (n=8) and 188Re-PEI-MP (n=12) 
respectively. When tumor reached the appropriate volume, Na188ReO4 and 188Re-PEI-MP were 
administered by an intravenous injection in the tail vein (22-37MBq), with the animal anesthetized 
and previously placed on the gamma camera detector. Immediately, a dynamic acquisition 
followed, with a 128x128 matrix for 10 min (20 frames, 30 seconds). Static images (2 min) were 
performed with a 256x256 matrix, where each of the four groups was divided into two groups, of 
which one was imaged at 120 minutes, and the other at 240 minutes. For biodistribution 
proposes, mice were euthanized 2 and 4 hours after injection and organ samples where weighted 
and counted in a well-counter to obtain percentage injected activity per gram of organ (%ID/g).  
Results: The MTT assay showed that PEI-MP is not cytotoxic. The radiochemical purity of 188Re-
PEI-MP was ≥90%. Biodistribution results, with Na188ReO4, showed a higher uptake by the 
thyroid, bladder and stomach, following a normal biodistribution. The biodistribution with 188Re-
PEI-MP showed that the excretion of this complex occurs primarily through the renal system, with 
a small fraction being eliminated by the hepatobiliary system. In mice with osteosarcoma 
tumor/muscle ratio was greater than 1.0, and for mice with bladder carcinoma the tumor/muscle 
ratio was greater than 1.5. 
Conclusions: The 188Re-PEI-MP seems to be promising in the treatment of both types of cancer, 
but with a greater potential for bladder cancer. 
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